GeNeo study: results from the Belgian PRECISION initiative

Dr Philippe Aftimos, medical oncologist at Jules Bordet Institut Brussels, summarizes the poster he presented.

GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative.

To broaden therapeutic horizons for breast cancer patients, this study compares the application of agnostic comprehensive genomic profiling (CGP) with organ-directed next-generation sequencing (NGS). Preliminary findings indicate an increased array of clinical options for molecular-guided therapies, emphasizing the potential advantages of early integration of CGP into the treatment decision-making process.